Financial Results for Half year and Year Ended on 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Microcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dipna Pharmachem Ltd has submitted its financial results to BSE covering both the second half-year and the full financial year ended 31st March 2025. The filing typically includes standalone and possibly consolidated figures for revenue, expenses, operating profit, and net profit for the period. Investors should check the detailed results PDF for the exact numbers, segment performance, and any auditor observations. The full-year results will give a complete picture of how the company performed in FY25 compared to the previous year.
This is a routine regulatory filing of periodic results. The actual impact on shareholders depends on the specific numbers — investors should compare revenue and profit against prior periods and check for any audit qualifications or one-time items before drawing conclusions.